Drug name - Bunavail

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine Aug, 2032

(9 years from now)

US9522188 BDSI Abuse resistant transmucosal drug delivery device Apr, 2035

(12 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.